SKU: BECHOP

BioCeuticals ChondroPlex 120t


$7195

Product!

Description


ChondroPlex® combines clinically trialled glucosamine and chondroitin with methylsulfonylmethane (MSM) to provide a comprehensive joint formula. ChondroPlex® may help in slowing the progression of mild osteoarthritis of the knee, and provide temporary relief of symptoms including joint swelling, pain and reduced mobility.

Features:
  • Provides three key joint nutrients - glucosamine, chondroitin and MSM - in convenient tablet form.
  • Provides nutritional support for the maintenance of healthy joint structure and function.
  • Contains scientifically validated GlucosaGreen® glucosamine sulfate sodium chloride and Bioiberica's BioActive® chondroitin sulfate with OptiMSM® all at therapeutic doses.
  • Provides 1500mg of glucosamine, 800mg of chondroitin, and 1200mg of MSM per daily dose.
  • Helps to slow the progression of cartilage wear and joint space narrowing.
  • May relieve pain and symptoms associated with mild osteoarthritis.
  • May temporarily relieve swollen, aching joints and joint inflammation associated with mild arthritis.
  • May increase joint mobility in mild arthritis.
  • Uses a non-shellfish, non-GMO derived glucosamine, so is suitable for people with shellfish allergies.

 

Each tablet contains:

 

Glucosamine sulfate sodium chloride - GlucosaGreen®

628mg

equiv. glucosamine sulfate

500mg

Bovine sodium chondroitin sulfate - CS BioActive®

330mg

equiv. chondroitin sulfate

267mg

Dimethyl sulfone (methylsulfonylmethane - MSM) - OptiMSM®

400mg


No added dairy, gluten, shellfish, soy protein.
  • If symptoms persist, consult your healthcare practitioner.
  • Contains 240mg of sodium per daily dose.
  • If you have any pre-existing conditions, are on any medications, always talk to your health professional before use.
  • Some products should be ceased at least two weeks before any elective surgery, please confirm with your health professional.
  • Always read the label. Use only as directed.

Prescribing Information:
  • The use of glucosamine sulfate, chondroitin sulfate and MSM during pregnancy and lactation has not been scientifically evaluated.
  • The evidence suggests that glucosamine has no significant effect on blood glucose levels when given to patients, with or without type 2 diabetes, for up t three years. However, diabetic patients are advised to continue their regular monitoring of blood glucose levels when taking glucosamine.
  • Glucosamine, chondroitin and MSM are generally well tolerated, although mild gastrointestinal disturbances have been reported.
  • No signs of toxicity have been observed after oral administration of chondroitin. Dosages of up to 10g daily for up to six years have not been associated with adverse effects.
  • Research indicates that long-term intake of MSM at doses greater than 2g daily has no adverse effects.
  • Due to theoretical anticoagulant activity, use chondroitin with caution in patients with clotting disorders or medicated with anticoagulant/antiplatelet drugs.
  • Caution should be taken in patients with prostate cancer or those patients with increased prostate cancer risk. Although not shown in supplemental chondroitin sulfate, preliminary clinical research suggests that chondroitin sulfate proteoglycans (known to be structural components of a variety of human tissues), may be associated with the spread or recurrence of prostate cancer.
TGA Listed product with Aust L .

 Download TGA Public Summary for TGA published information including excipients, which are listed under 'Other Ingredients'.